About vaxxinova
At Vaxxinova, we develop, manufacture, and sell veterinary vaccines including our Newport Laboratories brand of whole-cell bacterins and viral vaccines, and vaccines based upon our proprietary SRP® technology.
Each vaccine you receive is fully supported by advanced molecular diagnostics and a team of qualified individuals with years of lab experience.
Guiding the Way for better animal health.
Maintaining the health of your animals is central to the success of any livestock operation Vaxxinova works to ensure that veterinarians and livestock producers are equipped with the preventative, diagnostic, and educational tools necessary to ensure peak performance. The livestock industry changes quickly, and these changes often bring unique disease challenges.
Our use of molecular biology techniques such as gene sequencing and DNA fingerprinting save valuable time in diagnosing complex problems. By genetically selecting specific virus strains, our team can create vaccines specifically targeted to the issues facing your animals. The world of animal health continues to evolve, and you will find Vaxxinova on the leading edge.
Staying on top of disease prevention and overall heard health issues is no small feat. Vaxxinova puts you on a winning team in this battle. No matter what challenges today’s changing environment brings, you can rest assured that the team at Vaxxinova is working to discover and implement the most cost-effective, cutting-edge tools to help you solve the problem.
Our Core Strengths
HISTORY OF VAXXINOVA
The beginning
Vaxxinova US, originally called Epitopix, began as the laboratory service division of Willmar Poultry Company (WPC) in Willmar, Minnesota. During the 1980s, WPC began to seek innovative ways to improve the health of its turkey breeding stock.
In order to combat Salmonella, E. coli, Pasteurella (fowl cholera), and Hemorrhagic Enteritis virus, WPC created a USDA licensed vaccine laboratory, and selected a premier team of scientists to pioneer novel vaccine technology. This team pursued a single vaccine that would prevent as many as 30 different serotypes of Salmonella commonly found in the production of poultry and livestock.
SRP TECHNOLOGY
Through many years of research, the team developed ground-breaking technology in the form of Siderophore Receptor Protein (SRP) vaccines. This revolutionary vaccine immunizes against bacterial infections utilizing a cell-free purified extract of SRPs. By 1997, vaccine made from the combined SRP of Salmonella, E. coli, and P. multocida was in widespread use across the WPC breeder operations in Minnesota.
EPITOPIX WAS FORMED
Epitopix, LLC was formed in 2002 to commercialize SRP technology, and to discover new vaccine technologies that improve animal health and human food safety.
Discovery and development continues today, to bring novel vaccine products to additional markets including livestock, poultry, and companion animals. Epitopix owns intellectual property rights to all of its discoveries and has out-licensed SRP Technology development rights for human medical applications to Syntiron, LLC.
In 2018, Epitopix became part of the Vaxxinova team to develop and distribute products in the United States, and in 2020 changed its name to Vaxxinova US to create a global branding strategy and unify its partnerships with its global affiliates.
INTRODUCTION OF NEWPORT LABORaToriES
In September, 2021, Vaxxinova US acquired Newport Laboratories from Boehringer Ingelheim. Newport had a very strong presence making autogenous (custom) vaccines for cattle and swine, as well as a state of the art diagnostic laboratory.
With complementary portfolios, the acquisition allowed for new synergies for producers and veterinarians.
VAXXINOVA US, INC. CONTINUES TO BE PRIVATELY HELD, AND HOLDS USDA ESTABLISHMENT LICENSE NO. 365 FOR THE MANUFACTURING OF VETERINARY BIOLOGICALS
Worthington office
1520 Prairie Drive
Worthington, MN 56187
(800) 220-2522
info.us@vaxxinova.com
Willmar office
1801 Biotech Ave NE
Willmar, MN 56201
(844) 777-8299 (SRP-VAXX)
info.us@vaxxinova.com
Copyright © 2024. All rights reserved.